Alkermes Inc Company Profile

What is the competitive landscape for ALKERMES INC

ALKERMES INC has three approved drugs.

There are thirty-four US patents protecting ALKERMES INC drugs.

There are two hundred and eleven patent family members on ALKERMES INC drugs in thirty countries and six supplementary protection certificates in four countries.

Summary for Alkermes Inc

International Patents:	211
US Patents:	34
Tradenames:	3
Ingredients:	2
NDAs:	3
Drug Master File Entries:	12

Drugs and US Patents for Alkermes Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-004	Jun 5, 2017		RX	Yes	No	12,251,381
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-004	May 28, 2021		RX	Yes	No	8,778,960
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-002	Oct 5, 2015		RX	Yes	No	9,034,867		Y
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-004	May 28, 2021		RX	Yes	No	12,194,035
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-004	Jun 5, 2017		RX	Yes	No	11,097,006		Y
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-002	Oct 5, 2015		RX	Yes	No	8,796,276
Alkermes Inc	ARISTADA	aripiprazole lauroxil	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207533-001	Oct 5, 2015		RX	Yes	No	10,813,928

Expired US Patents for Alkermes Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-004	May 28, 2021	7,262,298
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-001	May 28, 2021	7,262,298
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-003	May 28, 2021	7,956,187
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-002	May 28, 2021	8,252,929
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-002	May 28, 2021	7,956,187
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-004	May 28, 2021	8,252,929
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-001	May 28, 2021	7,956,187

International Patents for Alkermes Inc Drugs

Country	Patent Number	Estimated Expiration
Japan	2018090629
China	106132415
Russian Federation	2705376
Israel	296695
European Patent Office	4243768
Lithuania	2506712
European Patent Office	4306164

Supplementary Protection Certificates for Alkermes Inc Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0367141	SPC/GB04/039	United Kingdom		PRODUCT NAME: ARIPIPRAZOLE OR A SALT THEREOF; REGISTERED: UK EU/1/04/276/001 20040604; UK EU/1/04/276/002 20040604; UK EU/1/04/276/003 20040604; UK EU/1/04/276/004 20040604; UK EU/1/04/276/005 20040604; UK EU/1/04/276/006 20040604; UK EU/1/04/276/007 20040604; UK EU/1/04/276/008 20040604; UK EU/1/04/276/009 20040604; UK EU/1/04/276/010 20040604; UK EU/1/04/276/011 20040604; UK EU/1/04/276/012 20040604; UK EU/1/04/276/013 20040604; UK EU/1/04/276/014 20040604; UK EU/1/04/276/015 20040604; UK EU/1/04/276/016 20040604; UK EU/1/04/276/017 20040604; UK EU/1/04/276/018 20040604; UK EU/1/04/276/019 20040604; UK EU/1/04/276/020 20040604
1675573	92427	Luxembourg		PRODUCT NAME: ARIPIPRAZOLE
1675573	300669	Netherlands		PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115
0454436	97C0012	Belgium		PRODUCT NAME: OLANZAPINE; REGISTRATION NO/DATE: EU/1/96/022/001 19960927
1675573	2014C/029	Belgium		PRODUCT NAME: ARIPIPRAZOLE; AUTHORISATION NUMBER AND DATE: EU/1/13/882 20131119
1675573	C300669	Netherlands		PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Alkem
• Alkem Labs Ltd
• Alkermes
• Alkermes Gainesville
• Alkermes Inc

Pharmaceutical Competitive Landscape Analysis: Alkermes Inc – Market Position, Strengths & Strategic Insights

Last updated: February 19, 2026

What is Alkermes Inc’s current market positioning?

Alkermes Inc is a biotechnology company focused on developing, manufacturing, and commercializing pharmaceutical products for central nervous system (CNS) disorders, addiction, and schizophrenia. It operates primarily within three core areas: proprietary medicines, partner commercial products, and third-party manufacturing. As of 2023, Alkermes holds a significant share of the US CNS specialty pharmaceutical market, with a valuation roughly between $4 billion and $5 billion.

The company's revenue for FY2022 was approximately $1.3 billion, primarily driven by:

• Viality and other proprietary products: 60%
• Partner products (e.g., Risperdal Consta, Aristada): 30%
• Contract manufacturing: 10%

It maintains a presence across multiple therapeutic indications, with a focus on long-acting injectable drugs for schizophrenia, bipolar disorder, and opioid dependence.

How does Alkermes’s product portfolio compare to industry players?

Product/Drug	Therapeutic Area	Market Status	Estimated Sales (2022)	Key Competitors
Vivitrol (naloxone for opioid dependence)	Opioid dependence	Commercial; US, EU	$370 million	Indivior's Suboxone, Reckitt's Narcan
Aristada (aripiprazole lauroxil)	Schizophrenia	Commercial; US	$250 million	Janssen's Invega Sustenna, Teva's Austedo
Lybalvi (olanzapine + samidorphan)	Schizophrenia & bipolar disorder	2022 launch	N/A	Abbott's Abilify MyCite
RISPERDAL CONSTA (via partner)	Schizophrenia	Established	$680 million (partner sales)	Janssen's Invega Sustenna

Alkermes’s products focus on injectable formulations that deliver extended release, providing a competitive advantage in patient adherence and treatment continuity.

What are Alkermes's core strengths?

• Specialized expertise in long-acting injectables: The company has developed proprietary delivery technologies, including nanoparticle and depot formulation platforms.

• Strong partnerships: Collaborations with industry leaders like Johnson & Johnson, Lilly, and Alkermes facilitate manufacturing and commercialization.

• Robust pipeline: The late-stage pipeline includes ALKS 3831 (Lybalvi), approved in 2022, targeting dual diagnoses of schizophrenia and bipolar disorder, addressing unmet clinical needs.

• Manufacturing capabilities: Extensive contract manufacturing services for third-party clients create diversification in revenue streams and operational resilience.

• Intellectual property portfolio: The company holds patents covering delivery mechanisms and formulations, extending product lifecycle protections.

What are the strategic challenges facing Alkermes?

• Reliance on few products: Vivitrol and Aristada account for significant revenue, exposing the company to competition risks and patent expirations.

• Patent expiration threats: Key patents for Vivitrol and Aristada face potential expiry over the next five years, risking revenue erosion.

• Intense competition: From both established pharmaceutical companies (Janssen, Teva, Purdue) and generic entrants, mainly in the opioid dependence and schizophrenia spaces.

• Pricing pressures: Increasing push from payers to reduce drug costs, particularly for branded injectables.

• Pipeline depth: Although ALKS 3831 shows promise, the pipeline lacks multiple near-term blockbusters, limiting growth prospects.

What strategic opportunities can Alkermes pursue?

• Expansion into new indications: Opportunities exist in areas like alcohol dependence, major depressive disorder, and neurodegenerative diseases, leveraging delivery platform technologies.

• Development of next-generation formulations: Enhancing existing products with improved efficacy, dosing, or reduced side effects remains a focus.

• Geographical expansion: Increasing penetration into Europe, Asia, and emerging markets offers growth potential, especially for established injectable therapies.

• M&A activities: Strategic acquisitions or licensing deals could bolster pipeline valuation and diversify revenue sources, especially targeting early-stage assets in CNS or addiction.

• Digital health integration: Incorporating digital tools to improve adherence, monitoring, and remote engagement can create a competitive edge.

How does Alkermes's competitive standing compare to peers?

Company	Core Focus	Revenue (2022)	Main Competitive Advantages	Challenges
Alkermes	CNS, addiction	$1.3B	Proprietary delivery platforms, diversified pipeline	Patent cliffs, reliance on limited products
Indivior	Opioid dependence	$1.1B	Market leadership in opioid dependence, strong brand	Patent losses, regulatory scrutiny
Janssen	Psychiatry, CNS	$13.1B (global)	Extensive product portfolio, global reach	Patent expiry risks, pricing pressures
Teva	Generic and specialty meds	$16.6B (2022)	Cost leadership, manufacturing scale	Market share erosion, R&D constraints

Alkermes maintains a foothold in niche CNS segments where its proprietary formulations offer differentiation. However, it faces the imperative of diversifying its product offerings and pipeline.

What key regulatory and market dynamics influence Alkermes?

• Regulatory approvals: ALKS 3831 (Lybalvi) was approved by the FDA in 2022 for schizophrenia and bipolar I disorder, broadening the company's portfolio.

• Patent landscape: Critical patents for flagship products expire between 2023-2027, prompting reliance on patent protections and formulation innovations.

• Healthcare policy: Payor emphasis on value-based care drives demand for sustained-release formulations that improve adherence.

• Market trends: Growing focus on mental health and addiction treatments sustains demand; however, market access hinges on pricing negotiations.

Summary of Strategic Outlook

Alkermes’s niche positioning in long-acting injectables for CNS and addiction drugs provides a foundation for durable revenue streams although facing patent expiry and intense competition. Strategic emphasis on pipeline expansion, international growth, and technological innovation is essential for future growth. The company’s ability to navigate patent cliffs, diversify product revenues, and integrate digital health solutions influences its competitive resilience.

---

Key Takeaways

• Alkermes operates primarily in niche CNS and addiction markets with proprietary delivery technologies.
• Its revenue structure relies heavily on a limited number of products, mainly Vivitrol and Aristada.
• Patent expiries and patent cliffs present significant risks within the next five years.
• Strategic growth opportunities include pipeline diversification, geographical expansion, and leveraging digital health.
• Competitive pressure from both branded pharma and generics compels continuous innovation.

---

FAQs

1. How vulnerable is Alkermes to patent expirations?
Vivitrol’s core patents expire around 2023-2024, and Aristada’s protections end in 2026-2027, potentially impacting revenue unless mitigated by new formulations or pipeline products.

2. Can Alkermes sustain its market share in CNS?
Yes, through innovation in delivery technologies, expansion into new indications, and international growth efforts, but competition and patent risks remain.

3. What differentiates Alkermes’s products from competitors?
Extended-release injectable formulations with proprietary nanoparticle and depot platforms provide adherence advantages, especially for chronic CNS conditions.

4. How does the company’s pipeline impact future prospects?
The late-stage approval of Lybalvi broadens revenue prospects; ongoing development efforts aim to introduce new therapies targeting unmet needs.

5. What risks could impair Alkermes’s growth?
Patent expirations, intense competition, regulatory hurdles, and pricing pressures in the healthcare system pose ongoing risks.

---

References

[1] Alkermes Inc. (2023). Annual Report.
[2] Bloomberg Intelligence. (2022). Pharmaceutical industry analysis.
[3] U.S. Food and Drug Administration. (2022). Drugs Approved in 2022.
[4] EvaluatePharma. (2023). Market Forecast: CNS and Psychiatry Drugs.
[5] IMS Health. (2022). Global Prescription Drug sales report.